- 3 out of 8 patients achieved clinical response in the Phase 1/2a trial of MP0533 for AML.
- Accelerated dosing regimen led to over 50% blast reduction in 5 of 8 patients.
- MP0533 maintained an acceptable safety profile with ongoing cohort studies.
Molecular Partners (MOLN, Financial) has announced promising results from its ongoing Phase 1/2a clinical trial for MP0533, a tetraspecific T-cell engager targeting relapsed/refractory acute myeloid leukemia (AML). Presented at the EHA 2025 Congress, the latest data from cohort 8 showed that 3 out of 8 evaluable patients, representing over 30%, achieved a clinical response after the initial cycle.
In this cohort, the dosing regimen was accelerated, enabling patients to reach the target dose by day 12, compared to day 15 in previous cohorts. This adjustment facilitated prolonged therapeutic exposure, as evidenced by more than 50% blast reduction observed in 5 out of 8 patients. Additionally, one patient maintained a response beyond six months, underscoring the potential durability of MP0533's effects.
The safety profile of MP0533 in cohort 8 was deemed acceptable, supporting further dose optimization efforts in cohort 9, which is currently underway. These studies aim to enhance the depth and duration of responses, with initial data anticipated in the second half of 2025.
Looking ahead, Molecular Partners plans to evaluate MP0533 in combination with azacitidine and venetoclax in future cohorts, focusing on maximizing the therapeutic benefit for patients suffering from this challenging form of blood cancer.
